Monoethylglycinexylide formation in assessing pediatric donor liver function

Stephen J. Rossi, Timothy J. Schroeder, William H. Vine, Hassan H Hassan, David A. Gremse, Frederick C. Ryckman, Susan H. Pedersen, Amadeo J. Pesce, William F. Balistreri

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Lidocaine metabolism to monoethylglycinexylide (MEGX) has been described as a novel method to assess liver function in adult transplant donors and recipients. While this assay appears to offer a number of advantages over existing liver function tests, limited work has been done to evaluate its potential in the pediatric population. This study evaluated MEGX formation in potential pediatric liver donors (n = 35) and a control group of children (n = 16). The mean MEGX formation was significantly higher in pediatric donors than in the control group (156 ± 62 vs 106 ± 33 ng/ml, p < 0.05). No correlation with age, total bilirubin, liver transaminases, or alkaline phosphatase could be made within each group. Significant differences in MEGX levels were noted when each group was compared to its adult counterpart. Both pediatric donors and controls had greater mean MEGX formation than has been reported for adult donors and controls (156 ± 62 vs 127 ± 61 ng/ml, p < 0.05 and 106 ± 33 vs 72 ± 36 ng/ml, p < 0.05, respectively). Drugs that alter lidocaine pharmacokinetics and their potential influence on MEGX formation were evaluated in the pediatric donor group. Donors exposed to hepatic enzyme-inducing drugs had a higher mean MEGX formation (187 ± 60 vs 146 ± 63 ng/ml). No significant differences were noted between donors receiving and not receiving va-sopressors. In conclusion, the significant differences between pediatric and adult MEGX formation should be noted when establishing reference or normal ranges for this diagnostic test. Furthermore, concomitant drug therapy may significantly alter MEGX formation.

Original languageEnglish (US)
Pages (from-to)452-456
Number of pages5
JournalTherapeutic Drug Monitoring
Volume14
Issue number6
StatePublished - 1992
Externally publishedYes

Fingerprint

Pediatrics
Liver
Tissue Donors
Lidocaine
Drug therapy
Transplants
Reference Values
Pharmacokinetics
Transaminases
Bilirubin
Metabolism
Pharmaceutical Preparations
Control Groups
Alkaline Phosphatase
Liver Function Tests
Assays
Routine Diagnostic Tests
Enzymes
Drug Therapy

Keywords

  • Lidocaine metabolism
  • Liver function
  • Monoethylglycinexylidide
  • Pediatric
  • Transplant

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Public Health, Environmental and Occupational Health
  • Toxicology

Cite this

Rossi, S. J., Schroeder, T. J., Vine, W. H., Hassan, H. H., Gremse, D. A., Ryckman, F. C., ... Balistreri, W. F. (1992). Monoethylglycinexylide formation in assessing pediatric donor liver function. Therapeutic Drug Monitoring, 14(6), 452-456.

Monoethylglycinexylide formation in assessing pediatric donor liver function. / Rossi, Stephen J.; Schroeder, Timothy J.; Vine, William H.; Hassan, Hassan H; Gremse, David A.; Ryckman, Frederick C.; Pedersen, Susan H.; Pesce, Amadeo J.; Balistreri, William F.

In: Therapeutic Drug Monitoring, Vol. 14, No. 6, 1992, p. 452-456.

Research output: Contribution to journalArticle

Rossi, SJ, Schroeder, TJ, Vine, WH, Hassan, HH, Gremse, DA, Ryckman, FC, Pedersen, SH, Pesce, AJ & Balistreri, WF 1992, 'Monoethylglycinexylide formation in assessing pediatric donor liver function', Therapeutic Drug Monitoring, vol. 14, no. 6, pp. 452-456.
Rossi SJ, Schroeder TJ, Vine WH, Hassan HH, Gremse DA, Ryckman FC et al. Monoethylglycinexylide formation in assessing pediatric donor liver function. Therapeutic Drug Monitoring. 1992;14(6):452-456.
Rossi, Stephen J. ; Schroeder, Timothy J. ; Vine, William H. ; Hassan, Hassan H ; Gremse, David A. ; Ryckman, Frederick C. ; Pedersen, Susan H. ; Pesce, Amadeo J. ; Balistreri, William F. / Monoethylglycinexylide formation in assessing pediatric donor liver function. In: Therapeutic Drug Monitoring. 1992 ; Vol. 14, No. 6. pp. 452-456.
@article{98aa81d459884ad28e0684b95e00e44c,
title = "Monoethylglycinexylide formation in assessing pediatric donor liver function",
abstract = "Lidocaine metabolism to monoethylglycinexylide (MEGX) has been described as a novel method to assess liver function in adult transplant donors and recipients. While this assay appears to offer a number of advantages over existing liver function tests, limited work has been done to evaluate its potential in the pediatric population. This study evaluated MEGX formation in potential pediatric liver donors (n = 35) and a control group of children (n = 16). The mean MEGX formation was significantly higher in pediatric donors than in the control group (156 ± 62 vs 106 ± 33 ng/ml, p < 0.05). No correlation with age, total bilirubin, liver transaminases, or alkaline phosphatase could be made within each group. Significant differences in MEGX levels were noted when each group was compared to its adult counterpart. Both pediatric donors and controls had greater mean MEGX formation than has been reported for adult donors and controls (156 ± 62 vs 127 ± 61 ng/ml, p < 0.05 and 106 ± 33 vs 72 ± 36 ng/ml, p < 0.05, respectively). Drugs that alter lidocaine pharmacokinetics and their potential influence on MEGX formation were evaluated in the pediatric donor group. Donors exposed to hepatic enzyme-inducing drugs had a higher mean MEGX formation (187 ± 60 vs 146 ± 63 ng/ml). No significant differences were noted between donors receiving and not receiving va-sopressors. In conclusion, the significant differences between pediatric and adult MEGX formation should be noted when establishing reference or normal ranges for this diagnostic test. Furthermore, concomitant drug therapy may significantly alter MEGX formation.",
keywords = "Lidocaine metabolism, Liver function, Monoethylglycinexylidide, Pediatric, Transplant",
author = "Rossi, {Stephen J.} and Schroeder, {Timothy J.} and Vine, {William H.} and Hassan, {Hassan H} and Gremse, {David A.} and Ryckman, {Frederick C.} and Pedersen, {Susan H.} and Pesce, {Amadeo J.} and Balistreri, {William F.}",
year = "1992",
language = "English (US)",
volume = "14",
pages = "452--456",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Monoethylglycinexylide formation in assessing pediatric donor liver function

AU - Rossi, Stephen J.

AU - Schroeder, Timothy J.

AU - Vine, William H.

AU - Hassan, Hassan H

AU - Gremse, David A.

AU - Ryckman, Frederick C.

AU - Pedersen, Susan H.

AU - Pesce, Amadeo J.

AU - Balistreri, William F.

PY - 1992

Y1 - 1992

N2 - Lidocaine metabolism to monoethylglycinexylide (MEGX) has been described as a novel method to assess liver function in adult transplant donors and recipients. While this assay appears to offer a number of advantages over existing liver function tests, limited work has been done to evaluate its potential in the pediatric population. This study evaluated MEGX formation in potential pediatric liver donors (n = 35) and a control group of children (n = 16). The mean MEGX formation was significantly higher in pediatric donors than in the control group (156 ± 62 vs 106 ± 33 ng/ml, p < 0.05). No correlation with age, total bilirubin, liver transaminases, or alkaline phosphatase could be made within each group. Significant differences in MEGX levels were noted when each group was compared to its adult counterpart. Both pediatric donors and controls had greater mean MEGX formation than has been reported for adult donors and controls (156 ± 62 vs 127 ± 61 ng/ml, p < 0.05 and 106 ± 33 vs 72 ± 36 ng/ml, p < 0.05, respectively). Drugs that alter lidocaine pharmacokinetics and their potential influence on MEGX formation were evaluated in the pediatric donor group. Donors exposed to hepatic enzyme-inducing drugs had a higher mean MEGX formation (187 ± 60 vs 146 ± 63 ng/ml). No significant differences were noted between donors receiving and not receiving va-sopressors. In conclusion, the significant differences between pediatric and adult MEGX formation should be noted when establishing reference or normal ranges for this diagnostic test. Furthermore, concomitant drug therapy may significantly alter MEGX formation.

AB - Lidocaine metabolism to monoethylglycinexylide (MEGX) has been described as a novel method to assess liver function in adult transplant donors and recipients. While this assay appears to offer a number of advantages over existing liver function tests, limited work has been done to evaluate its potential in the pediatric population. This study evaluated MEGX formation in potential pediatric liver donors (n = 35) and a control group of children (n = 16). The mean MEGX formation was significantly higher in pediatric donors than in the control group (156 ± 62 vs 106 ± 33 ng/ml, p < 0.05). No correlation with age, total bilirubin, liver transaminases, or alkaline phosphatase could be made within each group. Significant differences in MEGX levels were noted when each group was compared to its adult counterpart. Both pediatric donors and controls had greater mean MEGX formation than has been reported for adult donors and controls (156 ± 62 vs 127 ± 61 ng/ml, p < 0.05 and 106 ± 33 vs 72 ± 36 ng/ml, p < 0.05, respectively). Drugs that alter lidocaine pharmacokinetics and their potential influence on MEGX formation were evaluated in the pediatric donor group. Donors exposed to hepatic enzyme-inducing drugs had a higher mean MEGX formation (187 ± 60 vs 146 ± 63 ng/ml). No significant differences were noted between donors receiving and not receiving va-sopressors. In conclusion, the significant differences between pediatric and adult MEGX formation should be noted when establishing reference or normal ranges for this diagnostic test. Furthermore, concomitant drug therapy may significantly alter MEGX formation.

KW - Lidocaine metabolism

KW - Liver function

KW - Monoethylglycinexylidide

KW - Pediatric

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=0026445784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026445784&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 452

EP - 456

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 6

ER -